

**Biological activity of Pyrrole-
Imidazole polyamides *in vivo*.**

Thesis by
Jerzy O. Szablowski

In Partial Fulfillment of the Requirements for the
degree of
Doctor of Philosophy



CALIFORNIA INSTITUTE OF TECHNOLOGY
Pasadena, California
2015
(Defended May 1st, 2015)

ACKNOWLEDGEMENTS

I would like to thank my advisor, Peter Dervan, for the enthusiasm and support of the research projects during my time in his lab. Peter challenged me to stay focused on my projects while thinking broadly about the impact of my work on science and medicine. I am also particularly grateful for his guidance in learning how to communicate ideas, present my work, and seek advice when needed. Lastly, I am very grateful for the freedom I was given to pursue research projects, which was challenging, but also essential aspect of my training that I deeply appreciate.

I would also like to thank my committee chair, Frances Arnold, for advice and support, both during my graduate studies and when I had an invaluable opportunity to work in her laboratory during my undergraduate studies. The summer of 2007 was one of the highlights of my undergraduate studies and the problem solving skills I learned are still extremely useful, many years afterwards.

I am also thankful to Rob Phillips and Steve Mayo for serving on my thesis committee and for their advice during my first year of graduate school.

I am grateful to postdocs in our lab, Jevgenij Raskatov and Nick Nichols, with whom I worked on several projects. Jevgenij has given me a brilliant advice on science, but also taught me a lot about communication with other scientists. Nick has been an invaluable help during my studies and his efficiency, focus, and critical thinking have all been very helpful in my own development as a scientist. Work in this thesis would not have been possible without their help. I would also like to thank the staff of Caltech OLAR, and in particular Karen Lencioni and Gwen Williams, for their advice and help in our *in vivo* experiments.

I have had a privilege to interact with many great students, postdocs, Dervan group alums, and collaborators. I would like to extend my gratitude for intellectually stimulating discussions and advice from Thomas Martinez, Jim Puckett, Amanda Hargrove, Alissa Hare, JenJoo Kang, Tim Welch, Fei Yang, John Phillips, Amanda Silberstein, Dave Montgomery, Ben Li, Alexis Kurmis, Jamie Wang, Sam Weisbrod, Jordan Meier, Patrick Frost, and Bogdan Olenyuk.

Many other scientists have been an inspiration before my graduate studies and I am very grateful for their help. During my high school studies in Poland, I was lucky to take part in an internship in Zylicz lab at IIMCB, with then a doctoral student Dawid Walerych, who helped me with my first foray into science. During my undergraduate studies, I have received more support from professors Alan Jasanoff and Bob Langer than I could have possibly hoped for. I am particularly grateful for working with and learning from their graduate student Mikhail Shapiro. Sharing enthusiasm for science, working long hours, and engaging in creative discussions with him were the highlights of my time at MIT. I am also grateful for work done with Ed Boyden in Synthetic Neurobiology group, which was my first attempt at performing an independent project, which was as rewarding as it was challenging. Many of my fellow students and postdocs at MIT were an inspiration, including Brian Chow, Gil Westmeyer, Saad Zaheer, and my then neighbours in my dormitory.

Lastly, I am sincerely grateful for the support of my family – my parents, siblings and my wife Ji. The journey that led to this Ph.D. has been a long one and they have been on it with me for longer than anyone else. My parents have supported me in what must have looked impossible to any reasonable adult – attending a top research university in the US

after a Polish high school. I deeply appreciate that they allowed me to dream big despite the low odds of success. I have been lucky to meet Ji years ago. Throughout my Ph.D. studies her love and support were the reasons to come home every day, while her knowledge of medicine and advice helped me to stay focused on real-world implications of my work.

ABSTRACT

This thesis focuses on biological activity of pyrrole-imidazole polyamides *in vivo*. The work presented includes experiments underlining sequence selectivity of these compounds in living cells and potential methods to improve it. A large fraction of this thesis is devoted to activity of Py-Im in murine models of cancer. We investigated the pharmacokinetics and biodistribution of two compounds – targeted to 5'-WGGWCW-3' and 5'-WTWCGW-3' sequences – and characterized their activity by measuring their effects on tumor growth, gene expression *in vivo* and in tissue culture, and their effects on physiology of tumors. The initial theoretical studies suggested that a large fraction of genomic sites are bound by Py-Im polyamides non-specifically and experimental data shows that the programmed binding sequence is not a sole determinant of the patterns of gene regulation. Despite the likely presence of non-specific effects of Py-Im polyamides in living cells, *in vivo* administration of Py-Im polyamides resulted in tolerable host toxicity and anti-tumor activity. Py-Im polyamide targeted to Estrogen Receptor Response Element showed downregulation of ER-driven gene expression in tumor cells, while the compound targeted to hypoxia response element reduced vascularization of tumors and their growth rate, induced apoptosis of cells in hypoxic areas and reduced expression of proangiogenic and prometastatic factors. Further studies, showed that polyamides distributed to many of the tested tissues and their FITC-conjugates showed nuclear uptake. The gene expression effects were also present in murine tissues, such as liver and kidneys, indicating a potential for use for Py-Im polyamides in non-cancerous diseases.

TABLE OF CONTENTS

ACKNOWLEDGEMENTS.....	iii
ABSTRACT	vii
Table of Contents.....	ix
List of Illustrations and tables	xi
Introduction.....	1
Background and significance.....	1
The structure and function of Nucleic Acids.....	2
Molecular Recognition of DNA by minor groove binders.....	3
Modulating gene expression with Py-Im polyamides.....	7
Py-Im polyamides in treatment of disease.....	7
Scope of this work.....	10
Selectivity of Py-Im polyamides in tissue culture	15
Abstract	15
Introduction	16
Background.....	16
Evaluation of the genomic landscape of the GREs and	
polyamide binding sites	19
Selectivity of polyamides in A549 lung adenocarcinoma cells:	
Gene regulation studies.....	23
Cellular uptake of polyamides.....	36
Discussion and strategies for improving polyamides specificity in-cells.	38
Modeling kinetics and thermodynamics of polyamide binding in-cells.	38
Directions for a genome-wide evaluation of	
polyamide DNA-occupancy and action.....	44
Appendix A: materials and methods	44
Appendix B: Structures of GRE targeting polyamides	46
Appendix C: RT-qPCR primers used.....	47
Appendix D: Code	48
Appendix E: Full list of sequences of top 10% most	
Dexamethasone-induced GREs	51
Appendix F: DNA oligomer sequences for thermal denaturation assay	53
Appendix G: Code for modeling genomic distribution of	
GREs and Transcription Starting Sites	54
References.....	56
Activity of a Py-Im Polyamide Targeted to the Estrogen Response Element	59
Abstract	60
Introduction	61
Materials and Methods	63
Results.....	69
Discussion.....	83

Conclusion.....	88
Tables.....	89
References.....	91
Tumor Xenograft Uptake of a Pyrrole–Imidazole (Py-Im) Polyamide	
Varies as a Function of Cell Line Grafted.....	97
Abstract.....	98
Introduction.....	99
Results.....	101
Discussion.....	110
Conclusions.....	115
Experimental Section.....	116
Acknowledgements.....	118
An HRE-binding polyamide impairs adaptation of tumors to hypoxia.....	124
Abstract.....	125
Introduction.....	126
Results.....	130
Discussion.....	144
Conclusions.....	147
Materials and Methods.....	148
Acknowledgements.....	155
References.....	156
Preclinical development of Py-Im polyamides as therapeutics	
for multiple myeloma.....	159
Introduction.....	160
Results.....	166
References.....	184
A brief study of systemic effects of Py-im polyamide targeted to	
Hypoxia-Response Element.....	188
Introduction.....	189
Results and Discussion.....	189
References.....	192
Index.....	193

LIST OF ILLUSTRATIONS AND TABLES

Figure 1.1 Pairing rules and the structure of DNA.....	3
Figure 1.2 Example structure and DNA-binding motifs of transcription factors. .	4
Figure 1.3 Molecular recognition of DNA minor groove by a hairpin Py-Im polyamide.....	6
Figure 1.4. Commonly used murine cancer models: subcutaneous and orthotopic xenografts and genetically engineered models.	8
Figure 2.1 X-ray crystal structure of a Glucocorticoid Receptor (GR) bound to DNA.....	21
Figure 2.2 Modeling genomic distribution of GREs in relation to transcription starting sites (TSS).....	22
Figure 2.3 Characterizing DNA sequences binding GR.....	23
Figure 2.4 Orthogonality and targeting sites of three polyamides recognizing the most GREs	24
Figure 2.5 Analysis of levels of expression induced by Dexamethasone.....	25
Figure 2.6 Analysis of levels of expression of genes induced by Dex and inhibited by polyamides 1 and 2.....	26
Figure 2.8 Library of synthesized polyamides.....	31
Figure 2.9 Inhibition of a panel of Dex induced genes by polyamide 4	31
Figure 2.10 Downregulation of Dex induced genes using polyamide targeting the same sequence, but with different structures.....	32
Figure 2.11 Analysis of levels of expression of genes induced by Dex and inhibited by polyamide 13.....	33
Figure 2.12 Downregulation of Dex-induced genes using Py-Im polyamides.. .	35
Figure 2.13 Thermal denaturation assay on GREs and DNA oligos.....	36
Figure 2.14 Nuclear uptake of polyamides.	37
Figure 2.15 Trafficking dynamics of polyamides in living cells.	39
Figure 2.16 Modeling results for the three published compounds	42
Figure 2.17 Combinatorial targeting of polyamides.....	43
Figure 3.1 Ball-and-stick models of polyamides 1 to 6.	70
Figure 3.3 A, thermal denaturation assays of a duplex DNA oligonucleotide containing a half site ERE.	72
Figure 3.4. Representative data from luciferase and cytotoxicity (wst-1) assays for compounds 1-4.....	73
Figure 3.5 WST-1 cytotoxicity of 1 in T47D-KBLUC, LNCaP, A549, and U251 cells.	73
Figure 3.6 Quantitative RT-PCR analysis of Tff1 mRNA reduction after treatment with 1 for 96h is dose responsive.....	74
Figure 3.7 RNA-seq global transcriptome analysis.	76
Figure 3.8 Confirmation of genome-wide polyamide effects observed by RNA-seq.	77
Figure 3.9 Pharmacokinetics of 1.	78
Figure 3.10 Xenograft studies..	80

Figure 3.11. Confocal microscopy of live, cultured T47D-KBLUC cells.....	81
Figure 3.12 Tissue frozen sections of tissue extracted from xenograft-bearing mouse treated with polyamide 5.....	82
Figure 3.13 Confocal microscopy of live cells taken from T47D-KBLUC xenografts in mice treated with 5.	83
Table 3.1 Genes induced (or repressed) by either 1 (1 μ M) or E2 (10 nM).....	89
Table 3.2 Genes whose induction (or repression) by E2 is inhibited (or repressed by) 1 (1 μ M).....	90
Fig. 4.1. The C-14 radiolabeled Py-Im polyamide 1, targeted to the DNA sequence 5'-WGWWCW-3'.....	102
Fig. 4.2. Engraftment and polyamide administration schedules for the double flank experiment and the single flank versions.	103
Fig. 4.3. Vasculature of A549 and LNCap xenografts.....	104
Fig. 4.4. Microvessel density quantitated for LNCaP and A549 tumor sections.....	105
Fig. 4.5. Tumor levels of Py-Im polyamide 1 as a function of cell line engrafted.	106
Fig. 4.7. Concentrations of polyamide 1 in the host organs kidney, liver and lung as a function of cell line engrafted.....	107
Fig. 4.8. Tumor levels of Py-Im polyamide 1 as a function of time	108
Fig. 4.9. Extended tissue distribution analysis of Py-Im polyamide 1 in wild-type mice.....	110
Figure 5.1 Chemical structure and biological activity of Py-Im polyamides binding HRE sequence.	128
Figure 5.2. Pharmacokinetics, tissue distribution of and nuclear uptake of compounds 1-3 in-vivo.....	129
Figure 5.3 Py-Im polyamide 1 single-dose escalation study of toxicity.....	130
Figure 5.4 Polyamide 1 inhibits tumor growth..	131
Figure 5.5 Py-Im polyamide 1 shows nuclear uptake and attenuates tumor growth in GBM39 xenografts.....	132
Figure 5.6. Mouse weight loss during treatment with Py-Im polyamide 1.....	133
Figure 5.7 Polyamide 1 reduces microvessel density in tumors, without affecting blood vessel apoptosis or HUVEC tube formation on matrigel.....	134
Figure 5.8 Polyamide 1 reduces microvessel density of GBM39	135
Figure 5.9 Treatment with 1 decreases tumor proliferation, induces apoptosis in HIF-1a positive areas and does not lead to HIF-1a accumulation.....	137
Figure 5.10. Treatment with 1 increased reliance of tumor cells on proximity to vasculature.....	139
Figure 5.11 In vivo Effects of treatment with 1 are consistent between GBM39 and U251 xenografts.....	140
Figure 5.12. Treatment with 1 inhibits transcription of proangiogenic and prometastatic factors in tumors.....	142
Table 5.1 Percent changes in transcript expression of U251 tumors dosed with 1 according to <i>Schedule D</i>	143
Figure 5.13. Treatment with 1 inhibits tumor growth and decreases density	

of vasculature in a distinct way compared to an anti-VEGF therapy.	144
Table 5.2 Primers used in RT-qPCR experiments	148
Fig 6.1. Cartoon of HIF regulation showing O ₂ -dependent stabilization of HIF α , dimerization with HIF β , and gene regulation by HIF-PA	162
Fig. 6.2. Hypoxia-mediated apoptosis in MM cells cultured under normoxia (22%) or hypoxia (0.1%) for 72hr.	165
Fig. 6.3. Gene expression genes in hypoxia upon treatment with HIF-targetes siRNA and HIF-PA.....	167
Fig. 6.4 HIF-PA sensitizes MM cells to hypoxia.....	165
Fig. 6.5. HIF-PA inhibits 8226 tumor growth in SQ xenograft model.....	170
Fig. 6.6. Photomicrographs of serial tumor sections from control or HIF-PA treated mice stained for hypoxia (brown stain) and apoptosis (cleaved caspase 3).....	172
Fig. 6.7. Relation of apoptosis and hypoxia	173
Fig. 6.8. NOG mice challenged IV with 8226-LUC expressing cells	175
Fig. 6.9. HIF-PA inhibits 8226 tumor growth in BM.....	176
Fig. 6.10. Differential sensitivity of AKT/mTOR pathway in MM cells to 24hr hypoxia (0.1%) or CoCl ₂ (100 μ M) treatment.	180
Fig. 6.11. Combination of HIF-PA and Rapa treatment overcome resistance to hypoxia-mediated apoptosis.....	180
Fig. 7.1 Uptake of 1 in mouse tissues after IP injection.	202
Fig. 7.2. Py-Im polyamide 1 induces gene expression changes in mouse tissues.....	203